Back to Search
JARED WALZ, PHARMD, RPH
PHARMD, RPH
Pharmacist
NPI: 1720711229Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
21326-40(WI)
Research & Publications (20)
Influence of charged nanoparticles on colloidal forces: a molecular simulation study.
PMID 19548652·J Phys Chem B·2009
8-other
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
PMID 19229851·Prostate·2009
8-other
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study.
PMID 19293970·Can Urol Assoc J·2009
8-other
3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder.
PMID 19568477·J Psychiatry Neurosci·2009
8-other
Increased serum neurotrophin-4/5 levels in bipolar disorder.
PMID 19081579·J Psychiatr Res·2009
8-other
Continuous-wave Lyman-alpha generation with solid-state lasers.
PMID 19582040·Opt Express·2009
8-other
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
PMID 19027223·Eur Urol·2009
4-observational
Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study.
PMID 19021603·BJU Int·2009
8-other
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
PMID 19084864·J Urol·2009
4-observational
Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
PMID 18853417·Cancer·2008
8-other
Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
PMID 18553365·Cancer·2008
4-observational
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
PMID 18559597·Clin Cancer Res·2008
8-other
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
PMID 18467313·Ann Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 HIGHLAND AVE
MADISON, WI 53792 - Phone
- (508) 596-1990
Quick Facts
- NPI
- 1720711229
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile